PLAINSBORO, N.J., Sept. 25, 2015 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, today announced that the U.S. Food and Drug Administration (FDA) approved the new drug application for ...
People with diabetes have been hit with a five-month shortage of a vital medication. The Tresiba FlexTouch U100 insulin pen, which is manufactured by global pharmaceutical giant Novo Nordisk, is ...
PLAINSBORO, N.J., Jan. 26, 2016 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, today announced the availability of its newest insulin, Tresiba® (insulin degludec injection), a ...
Novo Nordisk announced that the Food and Drug Administration (FDA) has approved an expanded use for Tresiba (insulin degludec) injection to improve glycemic control in children and adolescents with ...
Novo Nordisk announced the launch of Tresiba (insulin degludec) injection indicated to improve glycemic control in adults with diabetes. Novo Nordisk announced the launch of Tresiba (insulin degludec) ...
PEOPLE with type 1 diabetes fear their lives could be at risk as the UK faces shortages of "vital" insulin. Insulin, which helps the body regulate blood sugar levels, is one of hundreds of drugs ...
Insulin degludec is available in FlexTouch ®, Novo Nordisk's latest prefilled insulin pen, and is offered in two concentrations enabling maximum doses of up to 80 and 160 units per single injection.
Novo Nordisk has received European approval for two new diabetes products – Tresiba and Ryzodeg – that are central to its growth plans for the next few years. Tresiba (insulin degludec) and Ryzodeg ...
Novo Nordisk NVO announced that Tresiba and Ryzodeg 70/30 have gained the long-awaited FDA approval for the treatment of diabetes mellitus in adults. Novo Nordisk intends to launch Tresiba in the U.S.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback